ArticleHealth affairs scholar2024
Medigap-guaranteed issue associated with Medicare Advantage disenrollment for beneficiaries administered a part B drug.
Article in Health affairs scholar, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Medicare Advantage Beneficiary Enrollment Decisions Following New Complex Conditions.JAMA health forum · 2026Article
- The financial implications of selective disenrollment from Medicare advantage.Health affairs scholar · 2026Article
- State Medigap Policies and Disenrollment From Medicare Advantage Among Beneficiaries With Cancer.JCO oncology practice · 2026Article
- Mental health care use after leaving Medicare Advantage for traditional Medicare.The American journal of managed care · 2025Article
- Medigap Regulations Provide Protections For Beneficiaries, Especially After Health Shocks, But May Raise Premiums.Health affairs (Project Hope) · 2025Article
- Medigap Protection and Plan Switching Among Medicare Advantage Enrollees With Cancer.JAMA health forum · 2025Article
- State-Level Consumer Protection Policies and Medigap Premiums and Plan Offerings.JAMA health forum · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
While many Medicare beneficiaries are enrolling in Medicare Advantage (MA), some beneficiaries may want to return to traditional Medicare and purchase Medigap, especially beneficiaries who have greater medical needs. Beyond minimal federal regulations, states impose additional regulations that impact Medigap affordability. Beneficiaries in some states have greater difficulty obtaining Medigap coverage because the states where they live allow Medigap insurers to experience rate the beneficiary, which can make Medigap insurance prohibitively expensive. We examined beneficiaries who received physician-administered drugs, which can be expensive and subject to high cost sharing, to see if disenrollment from MA for these beneficiaries was greater in states with Medigap consumer protection policy levels. In 2020, we find a 1.0% average baseline average probability of MA disenrollment. For beneficiaries who received a physician-administered drug in our sample, the probability of MA disenrollment is 3.7 (95% CI, 2.6-4.8;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.